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Abstract: Nanohydrogels based on natural polymers, such as polysaccharides, are gaining interest as
vehicles for therapeutic agents, as they can modify the pharmacokinetics and pharmacodynamics of
the carried drugs. In this work, hyaluronan-riboflavin nanohydrogels were tested in vivo in healthy
rats highlighting their lack of toxicity, even at high doses, and their different biodistribution with
respect to that of native hyaluronan. They were also exploited as carriers of a hydrophobic model
drug, the anti-inflammatory piroxicam, that was physically embedded within the nanohydrogels
by an autoclave treatment. The nanoformulation was tested by intravenous administration
showing an improvement of the pharmacokinetic parameters of the molecule. The obtained results
indicate that hyaluronan-based self-assembled nanohydrogels are suitable systems for low-soluble
drug administration, by increasing the dose as well as the circulation time of poorly available
therapeutic agents.
Keywords: nanohydrogels; hyaluronan; riboflavin; hydrophobic drugs; piroxicam;
biodistribution; pharmacokinetic
1. Introduction
Hyaluronic acid (HA) is a ubiquitous polysaccharide in the human body, crucial for many
biological functions. HA and its derivatives have been clinically used as medical products for about
thirty years [1]. More recently, HA has been employed as a building block for the preparation of
new biomaterials with applications in pharmacy, tissue engineering and regenerative medicine [2–5].
Among the biomedical applications, HA is exploited for the development of drug delivery systems,
thanks to its physicochemical properties, biodegradability, biocompatibility, low toxicity and ease of
chemical modification [6]. In addition, its ability to bind CD44 and RHAMM receptors enables active
targeting to certain tumors such as prostate, stomach or colon carcinoma, thus delivering the drugs
into the cells. Moreover, increased clinical CD44 expression has been positively correlated to metastasis.
This property represents a very useful strategy for a cancer-targeted drug delivery [7,8] and for the
Pharmaceutics 2018, 10, 213; doi:10.3390/pharmaceutics10040213 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2018, 10, 213 2 of 15
administration of chemotherapeutic drugs that are not capable of penetrating the cell membrane by
themselves (i.e., without an appropriate carrier) [9].
One of the main drawbacks in the use of HA is its rapid elimination from the systemic circulation
due to its recognition by the hyaluronic receptors of the reticuloendothelial system organs, such as
liver and spleen, and its subsequent degradation by hyaluronidases [10,11]. To reduce the uptake
and degradation of HA and to extend its circulation time, the polymer can be chemically modified or
crosslinked to form nanohydrogels (NHs). By means of a crosslinking process, the HA chains undergo
an alteration of their pharmacokinetic properties, thus prolonging their circulation time. In this sense,
some studies on HA-based nanocarriers, specifically developed for targeting to tumor tissues [12–14],
are recently published. The in vivo behavior of the HA-based nanocarriers shows an increase of the
circulation time of such nanoparticles. Moreover, it is shown that HA nanoparticles can efficiently
accumulate within tumors for at least two days, while unmodified HA is rapidly excreted from the
body after IV injection [15].
Among the HA-based NHs, a specific type is represented by the physically “self-assembled”
nanohydrogels, based on hydrophobically-modified HA, in which cholesterol or cholanic acid is
mostly used as lipophilic moieties [12,16,17]. These NHs can be formed in aqueous environments
by interactions among the hydrophobic moieties [18], promoted by several processes, such as
ultrasonication or nanoprecipitation [17]. Recently, a new method able to obtain simultaneously
the formation and the sterilization of self-assembling NHs by means of a standard autoclave cycle has
been developed [19]. These NHs can act as carriers of both hydrophilic and hydrophobic drugs [9,19],
as well as of several therapeutic proteins without affecting their activity [17,18].
Recently, a new type of amphiphilic HA derivative for NHs formation has been developed, using
a riboflavin tetra-ester as hydrophobic moiety [20]. The obtained hyaluronate-riboflavin derivative
(HA-Rfv) NHs show an improved stability with respect to HA-cholesterol based nanocarriers, along
with an enhanced drug loading capacity; in particular, an excellent behavior is shown in loading
hydrophobic molecules, thus leading to their enhanced apparent water-solubility and allowing to
obtain aqueous formulations of insoluble drugs [20,21]. For this purpose, piroxicam is selected as
model hydrophobic drug. Piroxicam is a nonsteroidal anti-inflammatory drug; it is commonly used
for the treatment of pain, tenderness, swelling, and stiffness caused by osteoarthritis and rheumatoid
arthritis. When administered by oral route, piroxicam can cause stomach and intestinal bleeding
and ulcers, weakness, dizziness and other manifestations. Intravenous route allows overcoming the
side effects but its poor solubility limits its use. In this sense, new formulations are required for the
optimization of its dosage regimen and for the improvement of efficacy.
In this study, the in vivo behavior of HA-Rfv NHs was investigated, in terms of toxicity and
biodistribution performances after systemic administration to healthy rats. Moreover, a model
hydrophobic drug, the anti-inflammatory piroxicam, was efficiently loaded within the NHs and
IV administered by tail vein to check the improvement of the pharmacokinetic parameters of the
nanoformulation compared to those of the free drug.
2. Materials and Methods
2.1. Materials
Hyaluronate tetrabutylammonium salt (HA-TBA, MW = 220 × 103) was a Contipro product
(Contipro a.s., Dolní Dobroucˇ, Czech Republic); riboflavin tetrabutyrate (Rfv) was purchased from
TCI Europe N.V., Zwijndrecht, Belgium; and N-methyl-pyrrolidone (NMP), 1,6-dibromohexane,
piroxicam, glycerol, dextrose monohydrate and rhodamine B isothiocyanate (rho) were obtained
from Sigma-Aldrich (Schnelldorf, Germany). Furthermore, diazepam (Valium, Roche, Barcelona,
Spain), ketamine (Ketolar, Parke-Davis, Madrid, Spain), atropine (atropine sulfate, Braun, Jaén, Spain),
heparin (Heparin Leo 5%, BYK ELMU, Madrid, Spain) and medical grade silicone tubes (Dow Corning
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Silastic, Fisher Scientific, Madrid, Spain); internal diameter 0.5 mm, outer diameter 0.94 mm) were
used. Other chemicals were reagent grade and were used without further purification.
2.2. Synthesis of Hyaluronate-Riboflavin Derivative
The synthesis of HA-Rfv was carried out according to the procedure described by Di
Meo et al. [20] 2’3’4’5’-tetrabutyryl-3-(6-bromohexyl) riboflavin (Rfv-Br) was first obtained from
2’3’4’5’-tetrabutyl-riboflavin and 1,6-dibromohexane in dry N,N-dimethylformamide; then, in a typical
reaction, the derivatization of HA-TBA with Rfv-Br was achieved by dissolving 300 mg of the polymer
in 30 mL of NMP, followed by the addition of 119 mg of Rfv-Br previously solubilized in 3 mL of
NMP to obtain a theoretical derivatization degree of 30% molRfv/molHA (mol of Rfv per mol of HA
repeating units). The reaction was left under vigorous magnetic stirring for 48 h at room temperature
in the dark; the mixture was then diluted with distilled water, transferred into a dialysis tube (cut-off
12,000–14,000) and dialyzed until water conductibity was about 1.5 µS. The final solution was frozen
in liquid nitrogen and freeze-dried (yield > 80%). The obtained product was analyzed by FT-IR ATR
(PerkinElmer Spectrum 100 Optica FT-IR spectrometer, Waltham, MA, USA) using a spectral resolution
of 4 cm−1 with 64 co-added scans over a spectral range of 4000–600 cm−1. The derivatization degree
of hyaluronan was assessed by UV-Vis spectroscopy (PerkinElmer LAMBDA 25 UV/Vis system,
Waltham, MA, USA) using a calibration curve of Rfv at λ = 445 nm in the concentration range of
3.125–50 µg/mL in DMSO.
Nanohydrogel Formation and Characterization
For the nanohydrogel (NHs) formation, a HA-Rfv dispersion (1.5 mg/mL) in distilled water was
autoclaved at 121 ◦C and 1.10 bar for 20 min (Juno Liarre autoclave, 230 VAC, 50/60 Hz, 12 A, 2000 W,
Casalfiumanese (BO), Italy), thus obtaining the NHs suspension [14]. The particle dimensions and PDI,
along with NHs formulation stability at 4 ◦C, were evaluated by means of dynamic light scattering
(DLS) using a Submicron ParticleSizer Autodilute Model 370 (Nicomp International Inc., Orlando,
FL, USA).
The critical aggregation concentration (CAC) of NHs was determined by analyzing a series of
HA-Rfv dispersions (from 0.01 to 2 mg/mL) as previously described (autoclave at 121 ◦C, 1.10 bar,
20 min). The samples were investigated by means of DLS measurements evaluating the NHs size and
the scattering intensity values [13]. The CAC value was determined by the intersection point of the
two linear trends by plotting intensity vs. concentration.
For the long-term storage experiments, NHs samples were freeze-dried: a cryoprotectant solution
(dextrose solution 20% w/v in water) was added to the NHs suspension (final dextrose concentration
1% w/v) and left under slow magnetic stirring overnight at 4 ◦C. The suspension was then frozen in
liquid nitrogen and freeze-dried. The product was then re-suspended in a suitable volume of water
(1.5 mg/mL) and vortexed for few minutes. The suspensions were analyzed by DLS to check the
dimensions and the PDI of the re-formed NHs.
2.3. Synthesis of Fluorescent Derivatives
For in vivo biodistribution tests, HA-Rfv NHs and native HA were both labeled with the
fluorescent dye rhodamine B isothiocyanate (NHs-rho and HA-rho).
For HA-rho synthesis, 160 mg of HA-TBA was dissolved in 64 mL of DMSO and 1.2 mL of rho
solution (9 mg/mL in DMSO) was added; the reaction was left under vigorous stirring for 5 h at room
temperature in the dark. Then, the product was extensively dialyzed and freeze-dried. Labeled NHs
were obtained by adding 1.3 mL of rho solution (9 mg/mL in DMSO) to 107 mL of NHs suspension
(1.5 mg/mL). The reaction was left under vigorous magnetic stirring for 5 h at room temperature in the
darkness. Then, the solution was dialyzed and freeze-dried after dextrose addition as cryoprotectant,
following the previously described procedure.
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Fluorescent NHs-rho were re-suspended in water (1.5 mg/mL) and observed by a confocal
microscope with laser scanning (Inverted Microscope Eclipse Ti-E, Nikon Instruments, Amsterdam,
the Netherlands) with an oil immersion 60× objective.
2.4. NHs Formulation for In Vivo Tests
To obtain NHs formulation suitable for intravenous administration, the osmolarity and pH of the
NHs suspensions were adjusted to 290 ± 10 mOsm/L and to pH 7.40 ± 0.05 by adding glycerol at
the final concentration of 2.28 w/v and the required volume of 0.1 M phosphate buffer to pH = 7.40.
The osmolarity of the preparations was measured using a Knauer K7400 (Berlin, Germany) osmometer
and the stability of NHs suspension at 4 ◦C in these conditions of osmolarity and pH was monitored
by DLS over a week.
2.5. Toxicity Studies
2.5.1. Cell Culture Conditions
Jurkat T lymphocytes cell line (kindly provided by the Department of Pharmacology of the
University of Valencia) were used between passages 4 and 30. Cells were grown and maintained
in 75-cm2 flasks in RPMI 1640 + GlutaMAX medium (GibcoBRL) supplemented with 10% fetal
bovine serum, 1% nonessential amino acids, 20 mM 2-[4-(2-hydroxyethyl)-1-piperazine]ethanesulfonic
acid, penicillin (10,000 units/mL), and streptomycin (10,000 µg/mL) (EuroClone) at 37 ◦C in
a humidified atmosphere with 5% CO2. All reagents were purchased by Sigma –Aldrich (Merck,
Schnelldorf, Germany)
2.5.2. Cytotoxicity Studies
Cytotoxicity assays were carried out on Jurkat T lymphocytes cells in 96-well microtiter plates
with flat-bottomed wells by MTT assay. In total, 25,000 cells resuspended in 200 µL of culture medium
were seeded into each well. Plates were incubated for 24 h at 37 ◦C in a 5% carbon dioxide atmosphere
and then the medium was replaced with a fresh medium containing NHs at the final concentration
of 225 µg/mL or 112 µg/mL per well. After 24, 48, or 72 h, 20 µL of a 5 mg/mL of MTT solution
were added to each well. After a new incubation period (3 h), the dark blue precipitate was isolated
by centrifugation and re-dissolved in DMSO. Absorbance measurements were taken at 570 nm with
a Labsystems Multiskan EX plate reader (ThermoFisher, Madrid, Spain) and the values were corrected
with reference to the measurement at 630 nm. Solvent alone and untreated cells were included as
negative controls. Assays were carried out in quadruplicate. Data were expressed as a percentage of
the absorbance of the untreated control.
2.6. In Vivo Tests: Biodistribution and Toxicity Assay
In this assay, the biodistribution of HA and HA-Rfv NHs in rats was evaluated by determining
the fluorescence emission of rhodamine in several vital organs following intravenous administration.
Moreover, blood analysis and liver biopsy were performed to evaluate the potential toxicity.
A solution of HA-rho in water (3 mg/mL) and a suspension of NHs-rho in water (concentration
equivalent to 4.5 mg/mL of NHs) were prepared. Concentrations were different for an optimized
fluorescence visualization because each condition was independently evaluated. The osmolarity and
pH of both formulations were adjusted to suitable values for intravenous administration (290 mOsm/L,
pH 7.4) by the addition of glycerol and phosphate buffer as previously described.
Experiments were performed according to the protocol approved by the Ethics Committee
(UMH-DI-MBS-02-15). Male Wistar rats weighing 280–300 g were anesthetized and were cannulated
in the jugular vein 24 h before each experiment, using a previously described technique [22,23].
The animals were divided into 9 groups (n = 4): 4 groups received HA-rho, 4 groups received NHs-rho,
and 1 group received saline serum as a control to study the baseline fluorescence of organs in absence
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of rhodamine. To facilitate the administration, rats were immobilized with the aid of a restrainer and
1.0 mL of the formulation tested was administered by intravenous injection into the tail vein; the rats
were then returned to their cages with food and water ad libitum. Animals receiving the formulations
were sacrificed at 5, 10, 24 and 48 h after administration, depending on the group.
At the predefined times, the animals were sacrificed by CO2 inhalation and immediately after the
thoracic cavity and the upper abdominal cavity were opened to exsanguinate. First, a blood sample
was taken from the heart. Then, a needle connected to a saline serum bag was inserted into the left
ventricle and the right atrial appendage was cut, allowing drainage of all organs and exsanguination.
At the end of this process, the following organs were excised: spleen, brain, heart, liver, lungs and
kidneys. The blood was centrifuged at 8000 rpm for 10 min and the supernatant (plasma) was taken.
The organs were weighed and homogenized. A sample of the hepatic tissue was collected before
homogenization and was placed into formol 20% to preserve it. Hepatic biopsies of these tissues were
carried out to by ACV LAB—Laboratorio de Analítica Clínica Veterinaria S.L. to analyze the potential
changes due to NHs accumulation.
Standard blood test parameters and hepatic profile specific parameters (focusing on cholesterol
triglyceride and hepatic enzymes levels) were determined at 24 h by ACV LAB—Laboratorio de
Analítica Clínica Veterinaria S.L. Parameter values of treated and non-treated rats obtained with the
different routinely laboratory techniques were compared using t-student to detect the existence of
significant differences at the 0.05 probability level. The Levene’s statistic was calculated to test the
homogeneity of variances and, depending on the result, post hoc tests were applied to determine
statistical significant difference among groups. The statistical analysis was made using SPSS, Version
22 (licensed to University of Valencia).
For the biodistribution analyses, plasma and 0.5 g organ homogenates samples were placed in
well plates and fluorescence images of rhodamine were taken by the InVivo FX Pro instrument (Bruker
BioSpin, Ettlingen, Germany) (excitation wavelength of 530 nm, emission wavelength of 600 nm;
software parameters: 40 s, 120 FOV, 5 mm focal plane). To remove the fluorescence baseline signal from
the organs and plasma, control fluorescence signal (rats treated with saline serum) was also evaluated.
The intensity signals were analyzed using ImageJ® software (ImageJ2 version, free software,
National Institute of Health, Bethesda, Maryland, USA). For each sample, the recorded fluorescence
was corrected with the fluorescence baseline of each organ or plasma and multiplying by the weight
of each organ or whole blood. The obtained results in liver and plasma were evaluated using the
t-student statistical test for independent samples with a 95% confidence interval.
2.7. Model Drug Loading into NHs
The anti-inflammatory drug piroxicam was chosen as a model hydrophobic molecule. The loading
process was carried out according to the previously reported procedure [19,20] that allows the
simultaneous formation of NHs and their loading. Briefly, a HA-Rfv dispersion in distilled water was
prepared (1.5 mg/mL, 30 mL) and left overnight stirring at room temperature. A stock solution of
piroxicam in acetone (20 mg in 5 mL) was separately prepared and vacuum evaporated in a glass
bottle leading the formation of a thin film of drug. The polymer dispersion was then added to the
bottle containing the drug film and let it hydrating for 1 h, then the sample was autoclaved (121 ◦C,
1.10 bar, 20 min) to allow the formation of NHs and the loading of the hydrophobic drug. Once the
samples were cooled down, they were centrifuged at 3000 rpm and 20 ◦C for 10 min (Ultracentrifuge
Sorvall WX ULTRA 80 Thermo Fisher Scientific, Madrid, Spain) to precipitate the unloaded drug.
The supernatant, containing the drug-loaded NHs, was analyzed by DLS to determine the
dimensions of the particles. The unloaded piroxicam, separated by centrifugation, was solubilized in
ethanol and quantified by HPLC using a Varian System, model 210, equipped with a Varian ProStar 325
UV-Vis detector and a Knauer C18 column, 250 mm × 4.6 mm (Eurospher II, 100-5 C18). The mobile
phase, a mixture of aqueous 0.1% v/v trifluoroacetic acid:acetonitrile 50:50 v/v, was used applying
an isocratic flux of 1 mL/min; the injection volume was 20 µL and the detection was performed
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at the wavelength of 356 nm. The quantification of the unloaded drug was evaluated by means of
a calibration curve obtained with piroxicam solutions with a range of concentrations from 15.63 µg/L
to 0.25 mg/mL in ethanol (r2 = 0.9994).
The difference between the initial drug amount (mi) and the unloaded drug (mu) gives the
encapsulation efficiency (%EE), according to Equation (1):
%EE =
mi −mu
mi
× 100 (1)
whereas the drug loading percentage (%DL) of the formulation was calculated using Equation (2):
%DL =
ml
p + ml
× 100 (2)
where ml = mi − mu is the amount of loaded drug, and p is the amount of NHs used.
2.8. Piroxicam Pharmacokinetics
To determine piroxicam pharmacokinetic parameters, the drug was administered both in solution
and encapsulated in NHs. Male Wistar rats 2–3 months old and 300 ± 10 g of weight were used and
divided into two groups (n = 8) depending on the administered formulation: the first one received
1.25 mL of a piroxicam solution 0.29 mg/mL solubilized in PBS:propilenglycol (50:50) and the second
group received 1.25 mL of an aqueous suspension of NHs loaded with piroxicam (equivalent to
0.29 mg/mL of piroxicam). The osmolarity and pH of the suspension were adjusted as described
above (290 mOsm/L, pH 7.4).
To perform in vivo assays, 24 h before the administration, a silicone catheter was implanted in
the jugular vein of the rats, following a previously validated technique [23]. Blood samples (0.2 mL)
were withdrawn, at previously established sampling times, using heparinized syringes and the
extracted volume was replaced with heparinized saline serum (1 IU/mL). Samples were immediately
centrifuged (9600 g, 10 min) to separate plasma; proteins were precipitated adding cold methanol
2:1 and by centrifugation (9600 g, 15 min). Samples were analyzed by HPLC using an Alliance
HPLC System (Waters, Barcelona, Spain). The pharmacokinetic analysis was carried out on mean
experimental plasma concentration values versus time. The total area, AUC0-∞, was calculated by the
trapezoidal rule for the data up to the last sampling time and adding the value of last experimental drug
concentration divided by terminal mono-exponential rate constant (Cp/k). To calculate clearance and
volume of distribution, two models of increasing complexity (one-compartment and two-compartment
models) were fitted with experimental data. To select the model that better described obtained data,
we evaluated R-squared value of the correlation between predicted versus observed values and sum of
squared residuals (SSR). An improvement of the suitability of SSR value by a more complex model was
statistically assessed with a Snedecor’s F test. The more complex model was accepted at a significance
value p < 0.05. Mean values and standard deviation of the parameters calculated with best model in
both groups (piroxicam in nanoparticles or as a free drug) were compared with two-tailed Student
t-test. The statistical analyses were done with the statistical package SPSS (Version 22, IBM United
States) licensed to Universidad Miguel Hernandez).
3. Results
3.1. Synthesis of the HA-Rfv Derivative and NHs Formation
By the reaction of HA-TBA with Rfv-Br, an amphiphilic polymer was obtained [20], capable of
self-assembling in aqueous environment under suitable conditions, as nanoprecipitation, ultrasound
or autoclave treatments [17–21], thus forming NHs. For the synthesis, the use of the tetrabutiryl-Rfv
reagent is due to the low solubility of not-esterified riboflavin in both aqueous and organic solvents;
similarly, the TBA+ salt of HA was used to carry out the nucleophilic substitution in an aprotic polar
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solvent (DMSO). As shown in Figure 1A, Rfv-Br reacts with the carboxyl groups of HA-TBA leading
to the formation of ester bonds. The obtained HA-Rfv polymer, recovered as a yellow freeze-dried
product, is a partial ester of HA: FT-IR analysis carried out in ATR mode on the dried product, as
reported in Figure S1, shows a notable stretching absorption at 1744 cm−1 due to the C=O stretching of
the ester groups formed between HA and Rfv, and of those of tetrabutyl moieties on the Rfv molecules.
The derivatization degree of the polymer was estimated to be 24% molRfv/molHA by means of UV-Vis
spectrometry in DMSO (Figure S2).
HA-Rfv presents physicochemical characteristics very different from those of the native polymer.
Water solubility is appreciably reduced by the hydrophobic Rfv moieties, thus the amphiphilic
derivative, when autoclaved, is able to self-assemble in nanostructures [20]. The autoclave process
allows the spontaneous formation of NHs by self-assembling of the HA-Rfv suspension due to the
high pressure and temperature conditions that promote intra- and inter-molecular interactions among
the hydrophobic groups of the HA-Rfv chains [19] (Figure 1B). FT-IR ATR analysis on dried NHs was
repeated to verify the stability of the system and the preservation of the polymer structure after the
autoclave treatment (Figure S1).
Pha maceutics 2018, 10, x FOR PEER REVIEW  7 of 15 
 
suspension due to the high pressure and temperature conditions that promote intra- a d inter-
molecular interactions among the hydrophobic groups of the HA- fv chai s [19] (Figur  1B). FT-IR 
ATR nalysis on dried NHs was rep ated to verify the stability of the system and the preserv tion of 
the polymer structure after the autoclave treatment (Figure S1). 
 
Figure 1. Scheme of HA-Rfv synthesis (A); and of NHs formation by autoclave treatment (B). 
The NHs showed a mean diameter of 200 ± 30 nm with a low PDI (0.22 ± 0.04). For long-term 
storage of NHs, a freeze-drying process was developed and optimized [17]. Actually, the NHs 
aqueous suspensions underwent several degradation processes, such as aggregation and hydrolysis, 
and, when loaded, they can lose the entrapped drug. To obtain a suitable formulation, it should be 
kept in mind that the elimination of water by lyophilization induces a phase separation due to the 
formation of a frozen solution and a cryoconcentrated suspension where the NHs and the other 
compounds used in the formulation are present. This high concentration of NHs can induce 
aggregation and, in some cases, their irreversible collapse; in addition, the crystallization of water 
causes mechanical stresses that can modify the NHs structure. For these reasons, before the freeze-
drying process, dextrose, as cryoprotectant, was added to the formulation (Cfin = 1% w/v); the dextrose 
molecules are able to form a compact matrix around NHs, thus preventing their aggregation and 
modification, induced by the mechanical stresses. 
No significant changes in size or in PDI values after dextrose addition, and after freeze-drying 
and re-suspension in water were evidenced (Figure S3 in Supplementary Materials). Thus, it can be 
stated that lyophilization carried out in the presence of a cryoprotectant is a suitable method for NHs 
conservation. In addition, NHs lyophilized and re-suspended in water were stable for a week at 4 °C 
(Figure S4 in Supplementary Materials). 
Another investigated parameter of NHs suspensions was the critical aggregation concentration 
(CAC). The CAC is defined as the minimum concentration of polymer at which NHs start forming 
by aggregation of the polymer chains. The DLS results, obtained with different samples, are reported 
in Figure 2: at low concentrations, few nanosized structures were detected, while the scattering 
intensity recorded at c = 0.25 mg/mL starts to increase exponentially due to the particulate dispersion, 
Figure 1. Scheme of HA-Rfv synthesis (A); and of NHs formation by autoclave treatment (B).
The s s o ed t 30 it 0.04). For long-ter
storage NHs, a freez -drying process was develop d an optimized [17]. Actually, he NHs aqueous
suspen ion u derwent several degrad tion processes, su h as aggreg tion and hydrolysis, and, when
loaded, they can lose the e trapped drug. To obtain a suita le form lation, it should be kept in mind
tha the elimination of water by lyophilization induces a phase separation du to the formati n of
a frozen solution and a cryoconcentr ted suspension where the NHs and the other compounds us d
in the formulation are present. This high conc ntration of NHs can induce aggregation and, i some
cases, their irreversible coll pse; in addition, the cryst llization of water causes mechanical stresses
that can modify the NHs structure. F r these reasons, before the freeze-drying process, dextros , as
Pharmaceutics 2018, 10, 213 8 of 15
cryoprotectant, was added to the formulation (Cfin = 1% w/v); the dextrose molecules are able to form
a compact matrix around NHs, thus preventing their aggregation and modification, induced by the
mechanical stresses.
No significant changes in size or in PDI values after dextrose addition, and after freeze-drying
and re-suspension in water were evidenced (Figure S3 in Supplementary Materials). Thus, it can be
stated that lyophilization carried out in the presence of a cryoprotectant is a suitable method for NHs
conservation. In addition, NHs lyophilized and re-suspended in water were stable for a week at 4 ◦C
(Figure S4 in Supplementary Materials).
Another investigated parameter of NHs suspensions was the critical aggregation concentration
(CAC). The CAC is defined as the minimum concentration of polymer at which NHs start forming
by aggregation of the polymer chains. The DLS results, obtained with different samples, are reported
in Figure 2: at low concentrations, few nanosized structures were detected, while the scattering
intensity recorded at c = 0.25 mg/mL starts to increase exponentially due to the particulate dispersion,
indicating the beginning of NHs formation [18]. The CAC value, expressed as the concentration of
HA-Rfv evaluated at the intersection between the two linearized regions, is 234 µg/mL.
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3.2. Synthesis of Fluorescent Derivatives
For the in vivo biodistribution tests, it was necessary to mark the NHs by means of a fluorescent
molecule to quantify the product in the various organs and tissues. At the same time, HA was also
labeled with the same dye for the in vivo comparison of the behavior of the two different materials,
HA and HA-Rfv.
Rhodamine B isothiocyanate was chosen as fluorescent marker: the reaction between the
isothiocyanate functional group of the dye and the primary hydroxyl group of the hyaluronate,
both in the native polymer and in the NHs, leads to the formation of a thiocarbamate bond, as shown
in the Figure S5A,B.
The purified NHs-rho were characterized after freeze-drying and re-suspension in water by
optical and fluorescence microscopy. As shown in Figure 3A, the unlabeled NHs show the intrinsic
fluorescence of the riboflavin molecule (green fluorescence), whereas the marked NHs show the typical
intense red fluorescence of rhodamine (Figure 3B), without noise background due to fluorescent
molecules not linked to the NHs.
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3.3. Toxicity Studies
3.3.1. Cell Toxicity Studies
NHs suspensions were examined for their potential cytotoxic activity. The effect of the formulation
was tested on Jurkat T lymphocytes cells using the colorimetric MTT assay to determine cell viability
after the cell exposition to various formulation concentrations (225 or 112 µg/mL), for 24, 48, 72 h.
Table 1 shows the percentage of cell survival after formulation exposition, taking as control value the
not exposed culture.
Table 1. Toxicity results expressed as percent of Jurkat T lymphocytes living cells.
% Living Cells
24 h 48 h 72 h
Control without NHs 100 100 100
NHs 112 µg/mL 100.0 ± 5.2 97.2 ± 4.3 100 ± 6.3
NHs 225 µg/mL 99.3 ± 4.8 100 ± 2.4 99.3 ± 5.1
3.3.2. In Vivo Assays
To assess the in vivo toxicity of the NHs, blood tests and hepatic biopsy were chosen as
representative. After administration of the NHs or saline serum by tail vein, standard blood analyses
and hepatic profile parameter values were determined and liver biopsies were performed to assess
the effect of the NHs. Table 2 shows the parameter values obtained after administration of NHs or
saline serum (control values of non-treated rats). Results show that there are no statistically significant
differences (p < 0.05) in all compared parameters.
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Table 2. Values of the standard blood test parameters.
Control NHs Administered
MEAN SD CV MEAN SD CV
White blood cells (G/L) 2.31 0.58 25.22 3.30 0.46 13.81
Red blood cells (T/L) 8.58 0.52 6.09 7.04 1.12 15.88
Hemoglobin (g/dL) 15.23 0.70 4.61 13.00 1.44 11.09
Hematocrit (%) 41.87 0.57 1.36 37.93 1.11 2.92
Mean corpuscular volume (fL) 48.90 2.52 5.16 49.07 2.35 4.78
Mean corpuscular hemoglobin (pg) 17.73 0.32 1.81 18.60 1.31 7.05
Mean corpuscular hemoglobin conc (g/dL) 36.37 1.23 3.39 37.87 2.71 7.17
Red blood cells distribution width 19.27 1.01 5.25 15.97 2.14 13.38
Platelets (G/L) 513.00 141.67 27.62 396.33 68.53 17.29
Mean platelets volume (fl) 6.90 0.20 2.90 7.47 0.12 1.55
Plateletcrit (%) 0.34 0.11 33.78 0.24 0.05 18.53
Platelet aggregates None None None None None None
Because of the main accumulation of HA and NHs in the liver, data for hepatic profile were
collected and the results are summarized in Table 3. After analyzing the hepatic profile parameters,
the results determined that there are no statistically significant differences between control group
animals and those exposed to NHs administration.
Table 3. Hepatic profile values obtained in both groups of rats in blood samples (n = 4).
Control NHs Administered
Value SD CV Value SD CV
Biliars Acids 31.00 5.66 18.25 24.33 1.15 4.75
Urea 41.00 4.24 10.35 37.67 7.09 18.84
Total Cholesterol 108.50 34.65 31.93 108.00 14.11 13.06
Creatinine 0.50 0.01 2.83 0.50 0.03 6.39
Triglycerids 82.50 27.58 33.43 74.33 23.76 31.96
Total Proteins 6.65 0.07 1.06 6.33 0.23 3.65
Total Bilirubin 0.10 0.01 7.44 0.14 0.05 35.80
CPK 332.50 146.37 44.02 376.33 94.11 25.01
Phosphatase alcaline 153.50 7.78 5.07 122.00 20.88 17.12
GGT <5 <5 <5 <5 <5 <5
GOT 100.00 5.66 5.66 106.00 11.14 10.51
GPT 32.50 4.95 15.23 33.67 3.06 9.07
LDH 462.00 124.45 26.94 435.67 98.65 22.64
Cholinesterase 0.24 0.00 0.00 0.28 0.04 14.61
Alpha fetoprotein 1.70 0.14 8.32 1.40 0.10 7.14
Albumin 2.77 0.15 5.37 2.18 0.12 5.65
Alpha1 globulin 1.90 0.10 5.21 1.74 0.09 5.35
Alpha2 globulin 0.61 0.01 2.32 0.89 0.11 12.73
Beta globulin 1.10 0.01 0.65 1.26 0.02 1.65
Gamma globulin 0.28 0.02 7.71 0.25 0.05 19.87
Albumin/globulin 0.72 0.05 6.92 0.52 0.02 3.98
Results from the blood tests and the hepatic biopsies indicate that NHs did not induce toxicity or
hepatotoxicity in the tested animals.
T-student was used to detect the existence of significant differences at the 0.05 probability level and
there were no significant differences between hepatic profile values obtained in both groups (Table 3).
The Levene’s statistic was calculated to test the homogeneity of variances and, according to these
results, a parametric test was applied to determine statistical significant difference between groups
in all parameters. The statistical analysis was made using SPSS, Version 22 (licensed to University
of Valencia).
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Figure 4 shows an example of an image taken from an animal of the control group and another
image from the liver of a rat treated with the NHs. Hepatic biopsies indicate that, any accumulation of
pigment in the hepatocytes, neither relevant inflammatory changes in the hepatic parenchyma nor
space portal were determined in both groups, the group of animals that were administered saline
serum and the group that was administered the formulation of NHs.
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3.4. Biodistribution of HA and NHs
The percentage of accumulation of NHs and HA polymer in organs was evaluated by
determining the fluorescence emitted by plasma and vital organs studied at different times after
intravenous administration.
Obtained results indicate that the fluorescence signal is almost null (less than 2%) in lungs, spleen,
heart and brain at any time, indicating that neither the polymer nor the NHs accumulate in these
organs. As expected, the liver is the main organ of biodistribution and constitutes 98.2% and 85.5% of
the fluorescence recorded at 48 h for HA and NHs, respectively (Figure S6 in Supplementary Materials).
Concerning kidney data, it is observed that NHs are eliminated by urinary excretion between
24–48 h after administration (5.7–9.1% of total fluorescence). However, the kidney fluorescence signal
in rats receiving the labeled polymer is practically nil at all times.
Finally, it is interesting to note that the NHs have a longer circulating time in blood, since at 24 h
the fluorescence signal is 41.3% and at 48 h it is 3.25%, in contrast to the HA polymer that recorded
intensity values lower than 1% at both times.
Figure 5 shows the evolution of the accumulation of the polymer and the NHs in plasma, liver
and kidneys. At time zero, it is assumed that the administered formulation is entirely in plasma and as
time progresses it is distributed mainly to liver.
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Figure 6 shows the evolution of disappearance in blood and the accumulation in liver of both
formulations. The difference between the percentage of distribution of NHs and polymer in liver and
plasma is statistically significant at 24 and 48 h after administration. The retention time of the NHs in
plasma is significantly higher than that of HA.
The results are consistent with those previously published [15,24]. The reticuloendothelial
system rapidly removes HA from the bloodstream, the polymer is extensively metabolized in hepatic
endothelial cells and its metabolites are reused in the body. Kidney uptake is low, and the lower is
the molecular weight of the polymer, the lower is the uptake in this organ [10]. HA-based NHs are
accumulated mainly in the liver, while the accumulation in other organs of the reticuloendothelial
system (kidneys and spleen) is variable [15,24]. Finally, in other organs, such as lungs, brain and heart,
the biodistribution of NHs is minimal [24].
Based on the obtained data, it is concluded that the main advantage of the NHs formulation
is that they have a significantly longer circulation time in blood compared to the starting polymer,
since the percentage of polymer is less than 1% at 24 h compared to 41.3% of NHs at this time.
This is an important goal to obtain stable plasma levels for longer time of low solubility drugs such
as piroxicam.Pharmaceutics 2018, 10, x FOR PEER REVIEW  12 of 15 
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3.5. Drug-Loaded NHs Formulation
Piroxicam, chosen as model hydrophobic drug, was loaded into NHs during the autoclaving
process [19] by hydrating a pr formed drug film and obtaining the formation and the loading of
NHs in one single step. The polymer concentr tion, as well as the initial mount f drug, were
previously optimized (data not show ) to obtain th best formul tion in terms of NHs size and PDI,
drug encapsulation efficiency (%EE) a d loading percentage (%DL).
The best formulation was obtained by using a polymer concentration of 1.5 mg/mL with a feed of
piroxicam in the ratio 1:2.25 with resp ct to polymer amount. I these conditions, NHs with suitable
dimensions (215± 10 nm, PDI = 0.22± 0.02), with the highest %EE = 49± 5, %DL = 18± 1%, and Cpir
= 0.32 ± 0.04 mg/mL, were obtained.
To obtain adequate osmolarity and pH values for the intravenous administration, a suitable
amount f glycerol (2.28% w/v for osmolarity djustment to 290 ± 10 mOs /L) and of phosphat
buffer solution (0.1 M, pH = 7.4, for adjustment to pH 7.40 ± 0.05, final concentration 0.01 M) wer
add d t the formulation, after freeze-drying and re-suspension in w ter Table S1 (Supplementary
Materials) shows how the size and PDI values of NHs were not influenced by the medium variation,
and Figure S7 reports the stability of the final f rmulation over time.
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3.6. Piroxicam Pharmacokinetics
Pharmacokinetic plasma profiles were determined after intravenous administration of a piroxicam
solution or piroxicam encapsulated in NHs. Plasma drug concentration versus time are reported
in Figure 7. Pharmacokinetic parameter values are listed in Table 4.
The best fit model was one-compartment model. It showed lower values of goodness of fits
parameters in comparison with two-compartment model: minor SSR value (1.47 × 10−3 vs. 1.54 ×
10−3) and less AIC value (−67.26 vs. −63.84). The one-compartment model fitted experimental data
significantly better than the two-compartment model. The one-compartment produced lower SSR
(1.47 × 10−3 vs. 1.54 × 10−3) and AIC (−67.26 vs. −63.84) values.Pharmaceutics 2018, 10, x FOR PEER REVIEW  13 of 15 
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Table 4. Piroxicam pharmacokinetic parameter values after IV administration as a free drug or as
NHs-piroxicam. S = significant statistical diff ces.
Piroxicam in
Solution
Piroxicam in
NHs
Ratio
(NHs/Solution) t-Student Statistics
kel (h−1) 0.22 ± 0.03 0.17 ± 0.03 0.78 0.034 S
Vd (l) 0.44 ± 0.04 0.39 ± 0.03 0.88 0.040 S
AUC (µg·h/mL) 3.81 ± 0.76 5.45 ± 0.46 1.43 0.003 S
Cl (l/h) 0.10 ± 0.02 0.07 ± 0.01 0.68 0.009 S
t1/2 (h) 3.21 ± 0.44 4.09 ± 0.59 1.28 0.028 S
The results show the suitability of NHs as vehicles for intravenous administration of drugs,
allowing modifications of the piroxicam pharmacokinetic behavior. The main difference in
pharmacokinetic parameters between piroxicam in solution and piroxicam embedded within the
NHs is clearance, which showed a 30% reduction. This reduction in clearanc allows maintaining
high concentrations of drug for a longer peri d, which implies a prolonged exposure to the drug.
This is confirmed by the AUC values, as indicators of drug exposure, with piroxicam loaded NH
presenting AUC values 43% higher than those of piroxicam in solution. Since clearance determines
administration frequency, the detected lower clearance should eventually allow a reduction of the
number of daily doses. On the other hand, piroxicam is a low solubility drug and, consequently, for its
IV administration, a high concentration of propylene glycol as a cosolvent should be used. High levels
of cosolvents are not always adequate in for ulations for human use. In this sense, NHs provide
a good opt on overcome this inconvenience l ading to an improved anti-inflammatory effect.
4. Conclusions
In this work the formation of NHs from an amphiphilic polymer obtained by hydrophobic
modification of HA with a riboflavin derivative wa studied. This polymer is able to s lf-assemble
and spontaneously forms NHs w n autoclaved in appropriate conditions. Fu thermore, during the
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autoclave process, it is possible to obtain, at the same time, sterile and drug-loaded NHs. Piroxicam,
chosen as model hydrophobic drug, was loaded in the NHs and the new system could act as drug
carrier. NHs suspensions, both drug loaded and non-loaded, showed an appropriate size (about
220 nm) with a low PDI value (<0.25) and a noticeable stability. Moreover, it was shown that
freeze-drying, after the addition of the selected cryoprotectant, is a suitable method for the long-term
conservation of NHs without variation of their dimensions.
Among the most important results, it must be evidenced that NH-Rfvs are not toxic, both
in vitro and in vivo; moreover, blood and hepatic analyses demonstrate their biocompatibility and
tolerability. This system is an excellent option for the encapsulation of low solubility drugs which
allows administering significantly higher doses of the drug with respect to the free drug.
After 24 h from the intravenous administration, more than 40% of the NHs were still in the
blood circulation, compared to less than 1% of free HA. Furthermore, NH-Rfvs allow modifying the
pharmacokinetic parameters of the loaded active ingredient, leading to a 30% clearance reduction
and a 43% AUC increase, compared to the drug solution administration. These innovative drug
administration systems appear to be quite fundamental in situations where it is important to prolong
circulation time in the body, as in the case of short biological half-life drugs.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/10/4/213/s1,
Figure S1: FT-IR ATR spectra of HA-Rfv, Figure S2: UV-Vis analysis of HA-Rfv, Figure S3: stability of empty
NHs after freeze-drying, Figure S4: stability of empty NHs aqueous suspension, Figure S5: schemes of the
syntheses of fluorescent HA and fluorescent NHs, Figure S6: biodistribution of HA and NHs, Figure S7: stability
of NHs-piroxicam formulation, Table S1: size and PDI values of NHs-piroxicam formulation.
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